Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 138 publications
Corrigendum to EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8.
Journal: Annals of the rheumatic diseases
Published: July 25, 2026
Advances in the use of Janus kinase inhibitors.
Journal: Current opinion in rheumatology
Published: March 17, 2026
Safety, biodistribution, and exploratory clinical outcomes of a novel intra-articular IL-1Ra gene therapy (PCRX-201) in moderate-to-severe knee osteoarthritis: 2-year results of a phase 1 study.
Journal: Annals of the rheumatic diseases
Published: March 13, 2026
Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?
Journal: The Journal of rheumatology
Published: August 01, 2025
EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: May 01, 2025
A plain language summary of the pooled safety results of adalimumab-adbm from the VOLTAIRE clinical trials in people with rheumatoid arthritis, Crohn's disease, and chronic plaque psoriasis.
Journal: Expert opinion on biological therapy
Published: March 12, 2025
A Severe Case of Nuclear Matrix Protein-2-Positive Dermatomyositis With Negative Malignancy Workup.
Journal: Cureus
Published: February 17, 2025
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme.
Journal: Rheumatology and therapy
Published: November 06, 2024
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn's disease, and chronic plaque psoriasis.
Journal: Expert opinion on biological therapy
Published: November 06, 2024
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.
Journal: RMD open
Published: September 26, 2024
EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.
Journal: Annals of the rheumatic diseases
Published: September 10, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: December 21, 2023
Last Updated: 09/26/2026